Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
EBOS Group Limited ( (AU:EBO) ) has issued an update.
EBOS Group Limited has notified the market of the lapse of 11,307 performance rights, identified as EBOAA securities, following the failure or impossibility of meeting the conditions attached to those rights. The cessation, effective 23 February 2026, represents a small adjustment to the company’s issued capital structure and highlights that certain performance hurdles under its incentive arrangements were not achieved.
The announcement does not signal any broader capital raising or buy-back activity but rather a routine compliance update regarding conditional equity that will not convert into shares. For investors, the impact is limited to a minor reduction in potential future dilution, with no immediate indication of changes to EBOS Group’s operational strategy or overall capital management policy.
The most recent analyst rating on (AU:EBO) stock is a Hold with a A$26.00 price target. To see the full list of analyst forecasts on EBOS Group Limited stock, see the AU:EBO Stock Forecast page.
More about EBOS Group Limited
EBOS Group Limited is a healthcare company listed on the ASX under the code EBO. It operates in the broader healthcare and pharmaceutical distribution sector, managing issued capital that includes performance-based equity incentives such as performance rights for employees or executives.
Average Trading Volume: 136,505
Technical Sentiment Signal: Sell
Current Market Cap: A$4.29B
See more data about EBO stock on TipRanks’ Stock Analysis page.